Market Overview

Opioid Drug Companies Rally On Hopes of Broader Settlement

Share:
Opioid Drug Companies Rally On Hopes of Broader Settlement

Shares of companies embroiled in the U.S. opioid crisis were trading sharply higher Wednesday following a Tuesday Wall Street Journal report that said three opioid drug distributors are in talks with state and local governments regarding a settlement agreement.

Distributors Discuss Deal

The three drug distributors — Cardinal Health (NYSE: CAH), McKesson Corporation (NYSE: MCK) and AmerisourceBergen Corp. (NYSE: ABC) — are negotiating a deal that envisages the companies collectively paying $18 billion over 18 years, the report said, citing people familiar with the discussions.

The three distributors are set to go on trial Monday in a lawsuit initiated by two Ohio counties. 

Johnson & Johnson (NYSE: JNJ) is also in talks to contribute additional money, the report said. 

Broader Settlement In The Works? 

If a settlement is reached, it could pave a way for a broad resolution to all opioid lawsuits filed against opioid drugmakers, distributors and pharmacies, the Journal said. 

The U.S. opioid crisis was fueled by pharma companies promoting prescription opioid pain relievers without properly warning of their addictive potential.

This has led to opioid overdoses and related deaths, costing the U.S. economy about $78.5 billion a year, including the cost of health care, lost productivity, addiction treatment and criminal involvement, according to the National Institute for Drug Abuse. 

Oxycontin maker Purdue Pharma filed for bankruptcy protection in mid-September, agreeing to settle litigation with 24 state attorneys general.

Johnson & Johnson was ordered to pay $572 million by the Cleveland District Court of Oklahoma, although the company has decided to contest the decision. The company has reached a $20.4-million settlement agreement with the Ohio counties of Cuyahoga and Summit.

Other companies such as Endo International PLC (NASDAQ: ENDP), Allergan plc (NYSE: AGN) and Mallinckrodt PLC (NYSE: MNK) have also negotiated settlement agreements.

In an Oct. 2 note, Morgan Stanley analyst David Lewis said he expects updates on whether Endo, J&J, Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and Mallinckrodt will push for a global opioid settlement that would be enacted through Purdue's Chapter 11 case.

The first trial is scheduled to begin on Oct. 21 in the Northern District Court of Ohio.

At last check:

  • McKesson shares were rallying 6.02% to $146.49. 
  • AmerisourceBergen was adding 4.96% to $87.33. 
  • Cardinal Health was advancing 4.01% to $49.83. 
  • Johnson & Johnson was moving up 2.74% to $136.46. 
  • Endo was rallying 21.49% to $4.24. 
  • Teva was gaining 5.38% to $7.34. 
  • Mallinckrodt was surging up 12.02% to $2.33. 
  • Allergan was edging up 0.49% to $170.99. 

Related Links:

Mallinckrodt Eyes Restructuring Ahead Of Cleveland Opioid Trial: 'Bankruptcy A Real Option'

Sell-Side Positive On Johnson & Johnson's Unexpected Ohio Opioid Settlement

Posted-In: Opioids Wall Street JournalNews Health Care Legal Media Trading Ideas General Best of Benzinga

 

Related Articles (ABC + CAH)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Piper Jaffray Upgrades AeroVironment On Valuation, Growth Opportunities

4 Stocks Nearing Key Breakouts